Last reviewed 2026-04-19 · How we verify

aspirin component of PA32540

POZEN · Phase 1 active Small molecule

aspirin component of PA32540 is a Small molecule drug developed by POZEN. It is currently in Phase 1 development.

At a glance

Generic name	aspirin component of PA32540
Sponsor	POZEN
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluate Relative Bioavailability of PA32540 (Asa/Omeprazole), Its Aspirin Component, and Ecotrin® in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

aspirin component of PA32540 CI brief — competitive landscape report
aspirin component of PA32540 updates RSS · CI watch RSS
POZEN portfolio CI

Frequently asked questions about aspirin component of PA32540

What is aspirin component of PA32540?

aspirin component of PA32540 is a Small molecule drug developed by POZEN.

Who makes aspirin component of PA32540?

aspirin component of PA32540 is developed by POZEN (see full POZEN pipeline at /company/pozen).

What development phase is aspirin component of PA32540 in?

aspirin component of PA32540 is in Phase 1.

Manufacturer: POZEN — full pipeline
Compare: aspirin component of PA32540 vs similar drugs
Pricing: aspirin component of PA32540 cost, discount & access